Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, has shown efficacy in ulcerative colitis and was approved by the US Food and Drug Administration (FDA ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh (mirikizumab) and AbbVie’s Skyrizi (risankizumab).

Biologics are medications made from antibodies that prevent certain proteins in the body from causing inflammation. Different types target different proteins. They’re usually injected or infused ...

First, the good news for the Indianapolis-based pharma, from the SERENITY phase 2 study in severely active Crohn’s disease. The trial showed patients treated with the drug mirikizumab saw ...

Study Rundown: Dermatomyositis is an autoimmune condition driven by type I interferon dysregulation. Current treatments fail to provide effective symptom control, highlighting the need for targeted ...

The Orlando Police Department has located 15-year-old Serenity Stanley, who was reported missing Saturday morning. Police said Serenity was last seen Friday afternoon in the area of Adventure Way ...

P-LLY This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Omvoh (mirikizumab-mrkz) as a treatment for ...

1 About Omvoh®Omvoh® (mirikizumab-mkrz) is an interleukin-23p19 antagonist indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults.